Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan Purchases 238,248 Shares

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan purchased 238,248 shares of Ventyx Biosciences stock in a transaction dated Friday, November 22nd. The shares were purchased at an average cost of $1.83 per share, for a total transaction of $435,993.84. Following the completion of the transaction, the chief executive officer now owns 1,913,276 shares of the company’s stock, valued at approximately $3,501,295.08. This represents a 14.22 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Raju Mohan also recently made the following trade(s):

• On Monday, November 25th, Raju Mohan acquired 261,752 shares of Ventyx Biosciences stock. The shares were acquired at an average cost of $2.01 per share, for a total transaction of $526,121.52.

Ventyx Biosciences Stock Up 11.4 %

VTYX traded up $0.21 during trading hours on Monday, hitting $2.06. 2,159,733 shares of the company’s stock were exchanged, compared to its average volume of 2,033,156. Ventyx Biosciences, Inc. has a 1-year low of $1.67 and a 1-year high of $11.48. The stock’s 50-day moving average is $2.19 and its two-hundred day moving average is $2.64. The stock has a market cap of $145.66 million, a price-to-earnings ratio of -0.87 and a beta of 0.37.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Wells Fargo & Company decreased their target price on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Canaccord Genuity Group lowered their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research note on Monday, November 11th. Finally, Oppenheimer reissued an “outperform” rating and set a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Institutional Trading of Ventyx Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Palumbo Wealth Management LLC acquired a new position in shares of Ventyx Biosciences during the 3rd quarter worth approximately $26,000. China Universal Asset Management Co. Ltd. increased its holdings in Ventyx Biosciences by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after buying an additional 5,310 shares during the last quarter. SG Americas Securities LLC bought a new stake in Ventyx Biosciences during the second quarter worth $32,000. Intech Investment Management LLC acquired a new stake in Ventyx Biosciences in the third quarter valued at $42,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after acquiring an additional 7,096 shares during the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.